文献速递肿瘤 PET/CT放射性药物与辐射防护

18F-FDG PET/CT在结核病中的应用:中期PET/CT能否预测患者临床结局?

18F-FDG PET/CT in Tuberculosis: Can Interim PET/CT Predict the Clinical Outcome of the Patients?
PubMed 文献 · Clin Nucl Med · 2020-01-01

该回顾前瞻性研究纳入87例肺结核及肺外结核患者,在抗结核治疗前及治疗开始后3至4个月各行一次全身18F-FDG PET/CT,用视觉分析和SUVmax评估治疗反应。中期PET/CT无应答者死亡率35%,应答者1.6%(P≤0.001),且无应答者抗结核治疗时间更长(P≤0.001)。

要点

  • 基线18F-FDG PET/CT在全部患者中阳性,72%患者检出临床未疑及的额外病变部位。
  • 中期PET/CT示13例完全代谢缓解、43例治疗反应良好、8例疾病稳定、23例疾病进展。
  • 无应答者死亡率为35%,应答者为1.6%(P≤0.001),无应答者抗结核治疗时间更长(P≤0.001)。

核心结论

  • 18F-FDG PET/CT是用于病变分布描绘和评估治疗反应的有价值影像手段。
  • 治疗开始后3至4个月进行的中期PET/CT所显示的治疗反应可预测抗结核治疗时长和患者临床结局。

研究设计与样本

  • 回顾前瞻性研究,纳入87例确诊肺结核和肺外结核患者(男女比46:41)。
  • 所有患者接受全身18F-FDG PET/CT用于初始评估,并在抗结核治疗开始后3至4个月接受随访扫描。
  • 采用视觉分析和半定量(SUVmax)分析评估扫描。

主要发现

  • 基线18F-FDG PET/CT扫描在所有患者中均为阳性,在72%患者中检出比临床怀疑更多的病变部位。
  • 中期PET/CT显示13例完全代谢缓解、43例治疗反应良好、8例疾病稳定、23例疾病进展。
  • 无应答者抗结核治疗时间长于应答者(P≤0.001)。
  • 随访期间87例患者中9例死亡,其中8例属于疾病进展组、1例属于疾病稳定组。
  • 无应答者死亡率为35%,应答者死亡率为1.6%(P≤0.001)。

关键数值与推荐

  • 中期扫描治疗反应分为完全代谢缓解、治疗反应良好、疾病稳定和疾病进展。
  • 完全代谢缓解、治疗反应良好和疾病稳定归为应答者,疾病进展归为无应答者。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE OF THE REPORT: Tuberculosis (TB) is a major health problem. Activated macrophages in TB lesions show high metabolic activity and can be assessed using F-FDG PET/CT. This retroprospective study was done to evaluate the utility of F-FDG PET/CT in initial assessment and therapeutic response in patients with TB. MATERIALS AND METHODS: Eighty-seven patients (male-to-female ratio, 46:41) diagnosed with pulmonary TB and extrapulmonary TB underwent whole-body F-FDG PET/CT for initial assessment and a follow-up scan 3 to 4 months after initiation of antitubercular therapy (ATT). Visual and semiquantitative (SUVmax) analyses were used for scan assessment. Treatment responses on interim scans were categorized as complete metabolic response (CMR), favorable response to therapy (FRT), stable disease (SD), and disease progression (DP). CMR, FRT, and SD cases were considered as responders and DP cases as nonresponders. Treatment response was correlated with clinical outcome (mortality) and ATT duration. RESULTS: Baseline F-FDG PET/CT scans were positive in all the patients and detected additional disease sites than suspected clinically in 72% patients. On interim PET/CT, 13 patients showed CMR, 43 showed FRT, 8 showed SD, and 23 showed DP. A longer duration of ATT was seen in nonresponders (P ≤ 0.001) than responders. During follow-up, 9/87 patients died, out of which 8 patients were of DP group and 1 patient belonged to SD. Nonresponders showed 35% mortality compared with 1.6% in the responder group (P ≤ 0.001). CONCLUSIONS: F-FDG PET/CT is a valuable imaging modality for disease mapping and assessing therapeutic response. Treatment response in the interim PET/CT done at 3 to 4 months predicted the duration of ATT and clinical outcome of the patients.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Sood A, Mittal BR, Modi M, et al. 18F-FDG PET/CT in Tuberculosis: Can Interim PET/CT Predict the Clinical Outcome of the Patients? Clin Nucl Med. 2020. PMID: 32108701. doi:10.1097/RLU.0000000000002968

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。